Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Launched by ANHUI PROVINCIAL HOSPITAL · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different imaging agents, [18F]F-PSMA-N5 and [18F]F-PSMA-1007, to see which one is better for diagnosing prostate cancer, checking for its recurrence, and finding if it has spread to other parts of the body. The researchers want to understand how these agents work in the body and how well they help doctors get the right information about prostate cancer in patients.

To participate in this trial, you need to be a man aged 18 to 90 who has been diagnosed with prostate cancer or is suspected of having it again after treatment. You’ll need to have some medical tests already done, including MRI images and details like PSA levels. If you join, you will undergo both imaging tests within two weeks and may need to have a biopsy afterward to confirm your diagnosis. It's important to note that not everyone can join; for example, if you have other cancers or certain health issues, you might not be eligible. This trial is currently looking for participants, so it could be a good opportunity to help advance prostate cancer diagnosis.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Aged from 18 to 90 years old;
• • Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
• • Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
• • simultaneous \[18F\]F-PSMA-N5 and \[18F\]F-PSMA-1007 examinations within two weeks;
• • Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
• • Sign informed consent.
• Exclusion Criteria:
• • Patients who cannot cooperate with the examination;
• • Concurrent malignant tumors;
• • Previous alcohol allergy;
• • Patients with liver and kidney dysfunction;
• • Other circumstances deemed by the investigator to be inappropriate for trial participation.